Back to Gene

IDH1 gene

Reviewed by Medicinsk Expert•Last updated: 2026-10-22•Gene

IDH1 gene

The IDH1 gene encodes an enzyme critical for cellular metabolism and protection against oxidative stress, with mutations often driving tumor formation and specific bone and blood disorders.

Normal Function

The IDH1 gene provides instructions for making an enzyme called isocitrate dehydrogenase 1. This enzyme is primarily found in the fluid-filled space inside cells (the cytoplasm) and in cellular structures called peroxisomes. In both locations, isocitrate dehydrogenase 1 converts a compound called isocitrate to another compound called 2-ketoglutarate. This reaction also produces a molecule called NADPH, which is necessary for the breakdown of fats for energy and protects cells from potentially harmful molecules called reactive oxygen species.

Health Conditions Related to Genetic Changes

Maffucci syndrome

Mutations in the IDH1 gene can cause Maffucci syndrome, a disorder characterized by multiple enchondromas (benign cartilage growths in bones) and hemangiomas (abnormal blood vessel growths in the skin). These mutations are somatic, meaning they occur during a person's lifetime and are not inherited. They result in mosaicism, where only some cells carry the mutation. These are gain-of-function mutations that cause the enzyme to produce D-2-hydroxyglutarate instead of its usual product.

Ollier disease

Mutations in the IDH1 gene also cause Ollier disease, a disorder similar to Maffucci syndrome but without the blood vessel abnormalities. Like Maffucci syndrome, these are somatic gain-of-function mutations resulting in mosaicism.

Cytogenetically normal acute myeloid leukemia

Mutations in the IDH1 gene have been identified in about 16 percent of people with cytogenetically normal acute myeloid leukemia (CN-AML). These somatic mutations change a single amino acid in the isocitrate dehydrogenase 1 enzyme. The resulting gain-of-function leads to the production of D-2-hydroxyglutarate, which may interfere with cell fate determination, causing immature blood cells to divide uncontrollably.

Other cancers

Somatic mutations in the IDH1 gene have been associated with other forms of cancer, including brain tumors called gliomas and bone tumors known as chondrosarcomas. These gain-of-function mutations lead to the abnormal production of D-2-hydroxyglutarate, which likely blocks the maturation of cells, resulting in the overproduction of immature cells and tumor formation.

Frequently Asked Questions

Yes. Several oral targeted therapies known as IDH1 inhibitors, such as ivosidenib, have received regulatory approval. These drugs work by selectively blocking the mutant IDH1 enzyme, stopping the production of the abnormal metabolite D-2-hydroxyglutarate (D-2-HG) and allowing abnormal cells to mature or undergo programmed cell death. IDH1 testing is routinely performed on tumor biopsies to identify patients who may benefit from these medications.
Mutated IDH1 gains an abnormal enzymatic function that converts alpha-ketoglutarate into D-2-hydroxyglutarate (D-2-HG), which is an oncometabolite. D-2-HG interferes with cellular differentiation and epigenetic regulation, triggering tumorigenesis. Clinicians can measure D-2-HG levels in tissue, urine, or blood as a biomarker to assess tumor activity and evaluate response to targeted treatment.
Patients require lifelong multidisciplinary surveillance by orthopedic oncologists and dermatologists. Because the benign cartilage tumors (enchondromas) carry an elevated risk of transforming into malignant chondrosarcomas, patients must be evaluated promptly for localized pain, rapid enlargement of an enchondroma, or night sweats. Periodic skeletal imaging with X-rays or MRI is standard to detect malignant changes early.
No, IDH1 mutations associated with conditions like Maffucci syndrome, Ollier disease, and acute myeloid leukemia are almost exclusively somatic mutations. This means they are acquired spontaneously in specific cell lines after conception rather than inherited through egg or sperm cells. Because the alteration does not exist in the germline cells, the risk of passing the condition to offspring is negligible.
Source: MedlinePlus, National Library of Medicine

MedlinePlus brings together authoritative health information from the National Library of Medicine (NLM), the National Institutes of Health (NIH), and other government agencies and health-related organizations.